Welcome to our dedicated page for Lucid Diagnostics news (Ticker: LUCD), a resource for investors and traders seeking the latest updates and insights on Lucid Diagnostics stock.
Lucid Diagnostics Inc. reports developments in commercial-stage cancer prevention diagnostics for patients with gastroesophageal reflux disease who are at risk for esophageal precancer and esophageal adenocarcinoma. The company, a subsidiary of PAVmed Inc., markets the EsoGuard Esophageal DNA Test and uses the EsoCheck Esophageal Cell Collection Device to collect samples through a brief, noninvasive office procedure.
Recurring updates cover EsoGuard commercialization, healthcare-system access, clinical evidence for esophageal precancer detection, quarterly business results, cash resources, and conference presentations. Lucid news also includes capital actions such as registered common stock offerings and related use of proceeds for working capital and general corporate purposes.
Lucid Diagnostics Inc. (Nasdaq: LUCD) has priced its initial public offering (IPO) of 5,000,000 shares at $14.00 per share, aiming for gross proceeds of $70 million. The offering will close around October 18, 2021. Additionally, underwriters have a 30-day option to purchase 750,000 extra shares. The stock is set to begin trading on Nasdaq on October 14, 2021. Lucid focuses on cancer prevention through its EsoGuard® test for at-risk GERD patients, which is a breakthrough device under FDA review.
Lucid Diagnostics Inc. has announced the pricing of its initial public offering (IPO) of 5 million shares at $14.00 per share, aiming to raise $70 million before expenses. The IPO will launch on October 14, 2021, and is expected to close on or around October 18, 2021. The underwriters have a 30-day option to purchase an additional 750,000 shares. Lucid, a subsidiary of PAVmed Inc., focuses on cancer prevention, particularly for patients suffering from gastroesophageal disease at risk of esophageal cancer, using its EsoGuard® diagnostic test.